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Double umbilical cord blood transplantation (UCBT) was developed as a strategy to circumvent the cell dose
limitation of single UCBT with a concomitant potential beneﬁt of lowering the rate of leukemia relapse.
Sustained hematopoiesis after double UCBT usually is derived from a single donor unit, as only a few patients
have been reported to display stable mixed-unit chimerism for varying periods of time. Explanations for the 1
unit dominance, predictors for identifying unit superiority, and persistence of long-term mixed-unit
chimerism remain elusive. Review of published literature revealed only 11 of 280 patients (4%) with mixed-
unit chimerism for at least 1 year after transplantation, with 3 patients receiving reduced-intensity condi-
tioning regimens. Mixed-unit chimerism was more likely if both units were closely HLA matched to each
other. Outcome data for patients with stable mixed-unit chimerism, for the most part, were scarcely reported.
Analysis of the small sample size revealed a potential advantage of stable mixed-unit chimerism on
enhancing the graft-versus-leukemia effect; however, deﬁnitive conclusions cannot be made on the effect of
mixed-unit chimerism on the rates of graft-versus-host disease. Therefore, gathering outcome data pro-
spectively in larger clinical series will help answer the question of whether stable mixed-unit chimerism is
either beneﬁcial and, therefore, should be strived for, detrimental and, thus, needs to be eliminated, or if it is
of no clinical consequence.
 2015 American Society for Blood and Marrow Transplantation.INTRODUCTION
Hematopoietic progenitor cells isolated from umbilical
cord blood (UCB) are an alternative graft source for alloge-
neic hematopoietic cell transplantation (AlloHCT) for those
patients lacking a suitable histo-identical sibling or a well-
matched adult unrelated donor. UCB has the advantage of
being readily available with a less stringent requirement for
human HLAmatching because of the immunologic naiveté of
UCB cells and the reduced numbers of lymphocytes in the
unit [1,2]. This graft source has become a standard thera-
peutic option for pediatric hematologic malignancy patients
and the result of using UCB compares favorably with unre-
lated blood and bone marrow grafts for AlloHCT [3]. In larger
children and adults, however, UCB transplantation (UCBT)
efﬁcacy is severely limited by the low progenitor cell dose
per recipient weight, leading to high risk of delayed or failure
of engraftment [4].edgments on page 618.
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ty for Blood and Marrow Transplantation.Various strategies to overcome this drawback include the
use of double (ie, dUCBT) rather than single-unit UCBT,
ex vivo expansion of UCB units, direct intrabone marrow
injection, and use of agents to enhance cell homing [5-8].
These interventions have been met with limited success.
Despite over a decade of using these approaches, no single
technology has emerged as a preferred approach. In the vast
majority of dUCBT cases, sustained engraftment of only 1
donor unit ultimately dominates and the other unit no longer
can be detected [9,10]. In rare cases, long-term hematopoi-
esis can be observed from both donor units in varying ratios,
a condition referred to as mixed-unit chimerism. To date, no
factors have been identiﬁed in these cases that reliably pre-
dict which unit will emerge as the dominant unit. The
mechanism for such single-unit dominance remains to be
elucidated [9,10]. The study of dUCBT is of even greater in-
terest given recent reports suggesting that dUCBT may be
associated with a reduced risk of leukemia relapse, which is
thought to possibly be a result of unit-to-unit allogeneic in-
teractions [11,12].
Chimerism results after transplantation are signiﬁcant. In
patients with malignant diseases, chimerism is primarily
used to detect early disease relapse, but it can also indicate
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H. Hashem, H.M. Lazarus / Biol Blood Marrow Transplant 21 (2015) 612e619 613impending rejection. In patients with nonmalignant disor-
ders, it is merely used to monitor successful engraftment.
The ability to detect the dominant unit early after trans-
plantation might be useful clinically, as delayed hematopoi-
etic recovery and immune reconstitution after dUCBT remain
ongoing limitations to more widespread adoption of the
approach using UCB as a donor graft source. Moreover, lack of
available donor lymphocyte infusion in UCBT (as potential
adoptive immunotherapy to improve engraftment or to treat
relapse) is problematic. Here, we review the dUCBT literature
regarding the frequency of mixed-unit chimerism occur-
rence, the clinical outcomes, and implications for UCB graft
selection.METHODS
We undertook a PubMed literature search for relevant clinical trials and
reviews (from January 1, 1985 to April 1, 2014) using the following key
words: umbilical cord blood, transplantation, double, mixed chimerism, and
dominance.We used those keywords in different combinations. We focused
on the studies that are related to our review subject of dominance and
mixed-unit chimerism in the setting of dUCBT. We also cross-referenced
review articles but focused on clinical studies and some preclinical trials,
regardless of patient ages and minimum numbers of patients in a trial or
report.
After successful AlloHCT, the recipient usually adopts the donor
hematopoietic system and becomes a full donor chimera. In some cases,
however, recipient hematopoietic cells remain and the patient instead be-
comes a mixed chimera. Split chimerism is used when the coexistence of
donor and recipient cells is observed in speciﬁc cellular lineage but not in
others. In the current article, we focused on hematopoietic progenitor cell
chimerism. A patient is considered to be a mixed chimera if he or she has 5%
to 95% of hematopoietic cells of donor origin [13]. After a period of transient
engraftment of both UCB units, a single unit emerges as the “winner” to
sustain long-term hematopoiesis, ie, at least 90% marrow reconstitution by
donor cells [14-16]. The time frame for determining dominance has not yet
been clariﬁed [17]. Usually, by day 21 after transplantation, single-unit
dominance can be detected in over 80% of patients, although dominance
as soon as 14 days after transplantation has been reported [10,18]. Sustained
detection of both UCB units in varying ratios over 21 days generally is
termed mixed-unit chimerism. Dominance reversion occurs when the frac-
tion of cells of the predominating UCB unit decline gradually and give up
dominance to the other unit in the state of mixed-unit chimerism. In an
analysis of 23 dUCBTaftermyeloablative conditioning (MAC), hematopoiesis
was observed from a single donor in 76% patients at day 21 and in 100% by
day 100 after transplantation [14]. Likewise, a review of 81 dUCBT after a
nonmyeloablative (NMA) regimen, single-donor chimerism was detectable
in 57%, 81%, and 100% of patients at day 21, 100, and 365, respectively [16].
Chimerism is often determined using bone marrow or blood samples
obtained at 21, 60, 100, 180, 360, and 720 days after transplantation, with
the use of additional time points as clinically indicated. Methods and
approaches for chimerism monitoring after dUCBT are discussed in detail by
Kristt et al. [19].SINGLE-UNIT DOMINANCE
Although single-unit dominance has beenwell described,
prior studies have not identiﬁed the mechanism or a reliable
method of predicting which will be the long-term engrafting
unit [9,10]. Verneris et al. stated “predicting the winning unit
seemed impossible and more like atmospheric noise” [20].
However, other investigators continue to attempt to deﬁne
predictors of UCB unit dominance. Gutman et al. showed
evidence that donor T cells from the engrafting UCB unit
speciﬁcally recognize the nonengrafting unit [18]. Taking
into consideration the intrinsic properties of the 2 infused
units and the immune interactions between the recipient
and the donor units, some studies have attempted to assess
whether single-unit dominance is inﬂuenced by the intrinsic
features of the UCB units. Table 1 depicts 8 clinical reports
addressing single-unit chimerism. The studies contained 8 to
136 patients; the majority of subjects received MAC regi-
mens and the most frequent disease indication was acute
Table 2
Candidate Factors Involved in Single-Unit Chimerism
Candidate Factors Supporting Citations Conditioning Regimen P Value
CD3þ cell dose Barker [14] MAC <.01
Avery [25] MAC .04
Ramirez [26] MAC þ NMA <.01 þ .05
Scaradavou [27] MAC þ NMA .0077
Kanda [28] MAC .042
CD34þ cell dose Avery [25] MAC þ NMA .008
Scaradavou [27] MAC þ NMA .0016
Haspel [29] RIC <.01
GM-CFU Brunstein [16] RIC .02
Yoo [30] MAC .006
HLA match (donor-recipient) Kai [24] MAC .0218
Ramirez [26] NMA .05
Order of i.v. infusion Ballen [15] RIC .049
Haspel [29] RIC .03
Route of infusion (i.v. versus intramarrow) Brunstein 6 (No advantage of intramarrow over i.v.
infusion for unit dominance)
MAC NS
Gender match Wallet [22] MAC þ RIC .094
HLA match (donor-donor) Avery [25] (closely HLA-matched units to each other were
most likely to have initial and sustained transient chimerism)
MAC þ NMA <.0001
TNC dose Kanda [28] MAC .02
Haspel [29] RIC .01
NS indicates not stated.
H. Hashem, H.M. Lazarus / Biol Blood Marrow Transplant 21 (2015) 612e619614leukemia. Not 1 identiﬁed factor can reliably predict the
dominant unit. In the majority of patients, transient dual
chimerism was replaced by sustained dominance of 1 unit
by 100 days after dUCBT, regardless of whether a patient
received MAC or reduced-intensity conditioning (RIC).
Factors Predictive for Single-Unit Dominance
A variety of speciﬁc factors have been examined for the
ability to reliably predict which unit will emerge as domi-
nant [9,10]. Table 2 lists some of the candidate factors,
including cell viability, infused total nucleated cell count,
CD34þ or CD3þ cell doses administered, gender matching
between recipient and graft, ABO blood group incom-
patibility, degree of HLA mismatch between the recipient
and each unit or between the 2 units, order of UCB unit
administration, and route of infusion (i.v. versus intra-
osseous) [6,9,14,15,22,24-30]. Despite most of the candidate
factors being statistically signiﬁcant in determining unit
dominance (as indicated by P values listed in the same table),
no single factor can be identiﬁed as being consistently
responsible (shown below).
Cellular characteristics of the graft
Barker and colleagues [14] previously reported that the
UCB unit with the higher CD3þ cell dose was more likely to
predominate. The differences in CD3þ cell doses, however,
were minimal, as the median infused CD3þ dose of the
predominating unit was .6  107 CD3þ/kg compared with
.4  107 CD3þ/kg of the nonsustained unit (P < .01). Ramirez
et al. [26] also showed the CD3þ dose to be associated with
single-unit dominance regardless of the conditioning regi-
men employed. Avery et al. [25] described an association
between CD3þ cell dose and CD34þ cell viability, in which
the dominant unit was more likely to be characterized by a
higher infused CD3þ cell dose and CD34þ cell viability> 75%.
Brunstein et al. [16] noted no difference between dominant
and nonsustained units in terms of total nucleated cell,
CD34þ, and CD3þ cell doses, but they described a higher
granulocyte-macrophage colony-forming unit (GM-CFU) in
the dominant unit. Yoo et al. [30] also showed GM-CFU to be
the only signiﬁcant factor predicting engraftment of thedominant unit. Finally, Scaradavou et al. [27] suggested that
units with low CD34þ cell viability (<75%) are less likely to
engraft upon coinfusion with a unit with high cell viability
(>75%). As noted above, some but not all studies were able to
show that CD3þ cell doses, CD34þ cell doses, and GM-CFU
were able to predict the dominant unit. These data demon-
strate that cellular characteristics and cell dose/unit selec-
tion, to date, are not reliable in predicting single-unit
dominance, ie, the intrinsic features of the graft are difﬁcult
to manipulate.
Degree of HLA match
The Minnesota group [14,25,27] reported that disparity
between the UCB unit and the recipient does not affect
dominance, whereas a closer HLA match between both units
is associated with an initial engraftment and transient
persistence of both units [25]. Ramirez et al. [26] showed,
only in the NMA setting, that better unit-recipient HLA
matchwas an independent factor associated with single-unit
dominance. It is possible that the inﬂuence of HLA matching
in the setting of NMA conditioning could be due to residual
host T cells interacting with UCB T cells; in the MAC setting,
these host cells will have been eradicated or rendered
nonfunctional. More recently, Kai et al. [24] analyzed 61
hematologic malignancy patients who underwent dUCBT
after MAC. A lower degree of HLA disparity in the host-
versus-graft direction was associated with unit dominance.
Again, HLAmatch between UCB units and recipient was not a
reliable predictive factor of single-unit dominance regardless
of the conditioning regimen. Alternatively, Avery et al. [25]
reported an interesting observation that closer HLA match
between both UCB units is associated with initial engraft-
ment of both units and the transient persistence of the
nondominant unit (P value <.0001; see below).
Order, route of infusion of UCB units, and gender matching
Two groups reported that when infusing 2 different UCB
units intravenously 3.5 to 4.5 hours apart, the dominant unit
usually was the unit infused ﬁrst [15,29]; the order of infu-
sion loses its signiﬁcancewhen units are infused sequentially
without a hiatus. Brunstein et al. [6] showed that neither
H. Hashem, H.M. Lazarus / Biol Blood Marrow Transplant 21 (2015) 612e619 615intravenous nor intraosseous administration of UCB units
were shown to confer a selective advantage in unit domi-
nance. Data from the SFGM-TC registry did not demonstrate
statistical signiﬁcance of gender matching with the recipient
in determining the dominant unit. This group did note,
however, that patient survival was improved after male UCB
engraftment among male recipients [22].
Conclusions for factors predictive of single-unit dominance
Although the above data indicate that several candidate
factors intrinsic to UCB units may suggest development of
unit dominance, no single factor was identiﬁed as being
consistently responsible.
Mechanisms for Single-Unit Dominance
The observation of increased acute graft-versus-host
disease (GVHD) and decreased relapse rates after dUCBT
suggest that immunologic interactions may underlie the
emergence of a winning unit. Additional immune inte-
ractions between the recipient and both donor units, as well
as graft-versus-graft immune interactions (to be discussed
below) may play a greater role in this process.
Although it is unclear if the data generated using a
xenograft immunodeﬁcient murine model will be predictive,
several preclinical studies suggested that an immune-
mediated effect could play a role in promoting the domi-
nance of 1 UCB unit [31-34]. Clinical studies strongly support
the importance of T cells to establish chimerism and ensure
hematopoietic cell engraftment [35]. As discussed above, the
concept that T cells also mediate dominance after dUCBT has
been described, but a consensus has yet to be reached
[14,18,24,36]. Few studies suggested graft-versus-graft im-
mune interactions as a mechanism for single-unit domi-
nance. Studies using immunodeﬁcient murine xenograft
models reported that donor T cells exert effects via in-
teractions with donor progenitor cells and their microenvi-
ronment after they showed that the addition of T cells
enhanced engraftment when compared with Tcelledepleted
mononuclear cells [33]. Kim et al. showed that single-unit
dominance was observed after cotransplantation of mo-
nonuclear cells. On the other hand, cotransplantation of
culture-expanded third-party mesenchymal stem cells re-
sults in more balanced coengraftment after dUCBT, which
can be partly, if not completely, attributed to a reduced
extent of donor deviation between the 2 grafts [31]. Yahata
et al. found that CD34 cells mediate unit dominance, spe-
ciﬁcally by a combination of CD4þ and CD8þ cells, indicating
that unit dominance is an immunologic phenomenon [37].
Other supporting data for a graft-versus-graft immune in-
teraction for unit dominance come from in vitro data by
Moretta et al. [36], who hypothesized that the dominant unit
is able to develop cytotoxic activity directed against activated
lymphocytes present in the other unit. The nondominant
unit is, thus, prevented from exerting alloantigen-speciﬁc
cytotoxic potential against both activated lymphocytes and
hematopoietic progenitor cell content of the dominant unit.
Other groups have suggested that the potential natural killer
(NK) alloreactivity of 1 unit might contribute to unit domi-
nance [38,39]. In conclusion, these results support the
importance of graft-versus-graft cell-mediated alloreactivity
as a principal mechanism promoting engraftment and
single-unit dominance. Trying to validate this strategy pro-
spectively in a clinical setting by applying 2-way mixed
lymphocyte culture may be helpful in predicting the domi-
nant unit.Gutman et al. [18] provided compelling evidence that
effector CD8þ T cells may play a critical role in the predom-
inant unit actively rejecting the losing unit. They postulated
that decreased relapse might be related to the early post-
transplantation immunologic interactions between the 2
infused units and residual host cells. If the dominant unit
could be predicted in advance, a well-matched, smaller unit
might be paired for infusion with a larger unit, both to
facilitate engraftment of the better matched unit and
enhance the graft-versus-leukemia (GVL) effect.
Newell et al. [40] showed a correlation of high early post-
transplantation donor CD3þ cells with the dominant unit,
suggesting rapid immune-mediated response. The same
group also demonstrated that infusion of a greater total CD3þ
cell dose, particularly of naïve CD3þ/CD8þ T cells, may play
an important role in determining single-unit dominance af-
ter dUCBT [41].
In conclusion, all previous clinical studies propose graft-
versus-graft immune interactions as an immune-mediated
mechanism of unit dominance. The mechanism of single-
unit dominance is likely multifactorial, involving intrinsic
features of the UCB units (summarized in Table 2) as well as
graft-versus-graft interactions and possibly host-graft in-
teractions. Identifying the mechanism for how 1 unit pre-
dominates could facilitate manipulation of UCB units by
upregulating immune reactivity of 1 unit. Moreover, under-
standing graft-versus-graft interactions may shed the light
on the host-graft interactions and, consequently, better un-
derstanding of GVL and GVHD.
MIXED-UNIT CHIMERISM
Table 3 depicts some of the reports illustrating the
persistence, for varying time periods, of both UCB units
(ie, mixed unit chimerism). The vast majority of prior reports
show emergence of single-unit dominance early (by 60 days)
and clearly by 12 months after transplantation. The data
in Table 3 indicate the existence of a stable, mixed-unit
chimerism state in some patients at 1 year after dUCBT. We
suggest the use of a more strict deﬁnition for stable mixed-
unit chimerism, ie, that condition in a patient in whom
both donor units are detectable 12 months after dUCBT.
Before 12 months after transplantation, we suggest this
clinical situation be termed transient mixed-unit chimerism,
as there remains a chance of skewing toward single-unit
dominance. This practice should help provide standardize
reporting of such patients in the future.
Dominance reversion is another novel situation that
occurs when the fraction of cells of the predominating UCB
unit decline gradually and give up dominance to the other
unit in the state of mixed-unit chimerism. One case
reported is a 15-year old boy who received a dUCBT for
acute lymphoblastic leukemia. He developed long-term
mixed-unit chimerism; later, dominance reversion from
unit B to unit A occurred as assessed on day 253 after
transplantation and was observed to persist during follow-
up of more than 16 months (497 days) later [42]. In a
phase I dUCBT clinical trial involving patients with hema-
tologic malignancies RIC regimen, another patient with
95% single donor chimerism on day 65 after trans-
plantation was reported to lose single-unit chimerism in
favor of mixed-unit chimerism over time. By day 177 after
transplantation, the last chimerism result showed the
dominant UCB unit contribution to hematopoiesis drop-
ped to 86% with the remaining 14% of hematopoiesis
came from the second UCB unit [29]. The patient died
Table 3
Clinical Studies Reporting Assessment of Mixed-Unit Chimerism
Author, yr Patients, n Age, Median
(Range), yr
Disease Regimen; No
of Patients
TNC Dose,  107/kg, and
CD34 Dose,  105/kg
Neutrophil
and Platelet
Engraftment,
Median, d
Outcome Chimerism Pattern Comment
Haspel, 2008 [29] 38 50 (18-65) AML, NHL, ALL,
CLL, HL
RIC (all
received ATG)
Dominant: 2.18 20 No outcome data 2 MUC at 16 and
24 mo
Higher TNC and CD34þ cell dose are
associated with unit dominanceNon-dom: 1.88
Dominant: 1.07 43
Non-dom: .56
Yen, 2008 [42] 1 15 ALL MAC (all
received ATG)
A: .87
B: 1.79
A: .31
B: .49
35
59
Disease free;
No GVHD
1 MUC at 16 mo (DR
from unit B to unit
A occurred at 170 d
First patient with DR in the setting
of MUC.
Berglund, 2009
Gertow,
2010 [43,44]
7 30 (20-59) AML, ALL, NHL MAC (5)
RIC (2) (all
received ATG)
3.4
1.1
31
53
Both patients are doing
clinically well with
no GVHD
2 MUC at 28 and
45 mo
Unit-unit HLA-C match combined
with ATG increase likelihood of MUC
Arachchillage,
2010 [45]
1 21 AML-M3 with CNS
disease
MAC A: 4.89
B: 3.2
NS
44
67
No GVHD;
No severe infection
1 MUC at 28 mo MUC may contribute to successful
outcome
Kang, 2010 [46] 61 9 (1-18) ALL, AML, SAA, JMML MAC (46
received ATG)
Dominant: 2.45
Non-dom: 2.55
Dominant: 1.16
Non-dom: .91
18
46
4-yr EFS 57%;
TRM 25% (mainly CMV);
aGVHD II-IV 52%
1 MUC at 1 yr Lower cell dose difference (<15%)
may decrease EFS and increase TRM
Kanda, 2011 [28] 27 33 (20-85) ALL, AML, CML, MDS MAC 4.3
1.2
24
37
2-yr DFS 52%;
2-yr TRM 28%;
aGVHD 37%
2 MUC at 2 yr Higher TNC and CD3þ were
associated with the dominant unit
Avery, 2011 [25] 84 36.5 (.9-66) AML, ALL, CML, CLL MAC (61) Dominant: 2.1 23 No outcome data 1 MUC at 1 yr Closer unit-unit HLA match is
associated with MUCNon-dom: 2.3
NMA (23) Dominant: .9 NS
Non-dom: .8
Yadav, 2013 [47] 1 2 JMML MAC A: 7.1
B: 6.4
NS
15
49
Grade III delayed aGVHD;
CMV infection
1 MUC at 9 mo Persistent of both units is more
likely if 6/6 match to each other
Milano, 2013 [41] 60 38 (18-52) ALL, AML MAC (46) Dominant: 2 MAC 25 No outcome data 1 MUC at 1 yr; MAC;
6/6 to each other
Higher CD3þ dose is associated with
unit dominanceNon-dom: 1.9 NS
RIC (14) Dominant: .12 RIC 13
Non-dom: .11 NS
DR indicates dominance reversion; A, unit A; B, unit B; CNS, central nervous system; EFS, event-free survival, JMML, juvenile myelomonocytic leukemia; TRM, treatment-related mortality; CMV, cytomegalovirus; aGVHD, actute
graft-versus-host disease; DFS, disease-free survival.
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ative disorder.
Table 3 shows 11 of 280 patients (4% of the total in the
studies) with mixed-unit chimerism at least 1 year after
transplantation; another patient was reported at 9 months
after transplantation. Three patients received RIC, although
as noted above, NMA conditioning is more often associated
with a period of mixed chimerism than MAC [16]. Although
there was a small sample size, it appears that mixed-unit
chimerism may be more prevalent with MAC. Gathering
such information prospectively from larger series will facil-
itate addressing this question. Additionally, for the 2 patients
who attained mixed-unit chimerism at 9 months and at
12 months after transplantation, both donor units were 6/6
HLA matched to each other; in a third patient, the UCB units
were at least 5/6 HLA matched to each other [25,41,47]. For
those 3 patients, 1 developed delayed, severe acute GVHD,
whereas no data were reported for the other 2 patients,
making it hard to reach any conclusions on the advantage of
unit-to-unit HLA match. Such data are in agreement with
Ponce et al. [48], who showed no advantage of unit-to-
unit HLA matching from the standpoint of acute GVHD.
Although continued study is appropriate, no data support the
consideration of unit-to-unit HLA match in UCB unit selec-
tion at this time. Outcome data on those patients with
mixed-unit chimerism are not reported for the most part.
Exceptions include 3 case reports; 2 patients did not have
GVHD [42,45] and a third developed delayed acute grade III
skin and gut GVHD [47]. All 3 patients had resistant leuke-
mias (high-risk acute promyelocytic leukemia, juvenile
myelomonocytic leukemia, and very high-risk acute lym-
phoblastic leukemia) but were in remission at the time of
report at 28, 9, and 16 months after dUCBT, respectively.
Despite the very small sample size, their reports showed that
an enhanced GVL effect is possible; however, one cannot
draw conclusions from these studies on the rates of GVHD.
Berglund et al. [44] and Gertow et al. [43], respectively,
used ﬂow cytometry and cytokine production to analyze the
phenotype and functionality of different cell subsets in cord
blood units in 2 patients with mixed-unit chimerism; they
showed that the 2 stable chimerism cord blood units are
different phenotypically and functionally. In comparison
with control patients having a single dominant UCB unit,
those 2 mixed-unit chimerism patients had more naïve
T cells and fewer CD45ROþCCR7 and CD4þ and CD8þ
memory T cells. These observation are in agreement with
Gutman et al. [18] and Yahata et al. [37] who showed that
unit dominance is mediated by a process that requires both
CD4þ and CD8þ cells, through a process that likely requires
either direct recognition of the MHC antigens or other
nonspeciﬁc effects.
Antithymocyte Globulin and HLA-C Matched UCB Units
Berglund et al. [44] observed long-term mixed unit
chimerism for more than 2 years in 2 of 7 patients, all of
whom received high-dose antithymocyte globulin (ATG,
8 mg/kg) in the course of myeloablative alternative donor
transplantations. They proposed that the high-dose ATG
facilitated tolerance between both cord units via T cell
depletion induced by ATG within already immunologically
naïve cord blood cells. The same group extended their
hypothesis by suggesting that HLA-C match and possible NK
cell tolerance between both units in combination with high-
dose ATG increases the likelihood of stable mixed-unit
chimerism [43,49]. As T cells after dUCBT both reconstitutemore slowly compared with adult hematopoietic cell sources
and usually are present at a much lower overall number, the
addition of a high-dose ATG greatly will reduce the potential
for T cellemediated rejection in any direction for a prolonged
period of time [50]. The lack of T cells allows for NK cells to
expand more freely. This could lead to tolerance in an HLA-C
matched situation between both units, as NK cell function is
regulated partly by inhibitory killer cell immunoglobulin-
like receptors (KIRs) that recognize certain HLA-C mole-
cules [36,51]. KIR-ligand mismatching between donor and
recipient has been shown to be beneﬁcial for a GVL effect in
haploidentical cell transplantation [38]. Further, with dUCBT,
KIR-ligand mismatch has been associated with a lower
relapse rate as well as better overall survival [39]. Moreover,
reduced relapse risk also has been reported for dUCBT in
comparison to single UCBT [11]. The roles of KIR and KIR-
ligand in the context of hematopoietic cell transplantation
have been investigated over the past 10 years. In trans-
plantations that are KIR-ligand mismatched in the graft-
versus-host direction, donor NK cells expressing inhibitory
KIRs, which do not recognize ligands on recipient targets, are
released from HLA inhibition and lead to less restrained,
more active NK cells. This situation results in clinically sig-
niﬁcant GVL effects. Better donor selection through high-
resolution HLA typing, including HLA-C, not routine at the
current time, may improve outcomes through enhanced GVL
effect [52].
In conclusion, studies showed that HLA-C match between
both donor units would increase the likelihood of stable
mixed-unit chimerism through tolerance induction between
both UCB units. Further, HLA-C mismatch between recipient
and donor will increase the chance of alloreactivity, as they
will not tolerate each other. Exploiting this NK cell effect to
enhance GVL could improve patient outcome after dUCBT.
SUMMARY AND FUTURE DIRECTIONS
To date, no factors reliably predict for single-unit domi-
nance or the coexistence of both units. The mechanism of
single UCB unit dominance has been investigated by many
groups and is most likely multifactorial. Speciﬁcally, this
condition appears to involve intrinsic features of the UCB
units, such as homing properties and proliferative poten-
tial of hematopoietic cells, graft-versus-graft immune in-
teractions mediated by T cells, as well as graft-versus-host
immune interactions [53-55]. Understanding those immune
interactions may help us predict the dominant unit, and
more importantly, could yield insights into the mechanisms
of GVHD and GVL responses and improve outcomes.
Regardless of these mechanistic questions, there remains
the issue of how this information might be used to beneﬁt
patients and improve clinical outcomes. For instance, is it
possible to reliably predict the “winning” unit in the future,
and if so, why might we want to do so? If the dominant unit
could be predicted, a well-matched smaller unit might be
paired with a more poorly matched larger unit to facilitate
engraftment of the better matched unit; perhaps the battle
for dominance might enhance GVL while the ultimate
dominance of a well-matched unit might lead to decreased
GVHD and treatment-related mortality. One area of interest,
but with a paucity of data in the literature, is the effect of the
type, intensity, and timing of the immune suppression
regimen or the timing of immune suppression withdrawal
on mixed-unit chimerism. This maneuver may or may not
contribute to the rapidity and severity of mixed-unit
chimerism or single-unit dominance. The Minnesota group
H. Hashem, H.M. Lazarus / Biol Blood Marrow Transplant 21 (2015) 612e619618has preliminary data on this subject. They believe that pro-
longed mixed double UCB chimerism is a reﬂection of 2-unit
tolerance; the relapse rate appears increased in mixed chi-
meras because of reduced alloreactivity [56]. Regarding im-
mune suppression withdrawal, this approach often differs
signiﬁcantly among centers and we are not aware of studies
examining immune suppression withdrawal and chimerism.
Given the wide variations in approach, it is quite difﬁcult to
reach conclusions at this time. This concept is an important
question to explore in future studies and collaboration
of centers that perform dUCBT would help answer that
question and also would allow a standardized analysis of
chimerism, given current differences between centers. The
delayed hematopoietic recovery and immune reconstitution
after dUCBT remain ongoing limitations and lack of available
donor lymphocyte infusions, as potential adoptive immu-
notherapy to improve engraftment or to treat relapse, is
problematic. The ability to detect the dominant unit might be
useful in such cases. New strategies that are now being
investigated include infusions of ex vivo expanded antiviral T
cells and the generation of CIK cells or NK cells typically
derived from small aliquots of residual cells obtained at time
of cord blood infusion. Reliable and early prediction of the
dominant unit would allow early selection of the appropriate
starting cells to be further manipulated in the development
of adoptive immunapies. Moreover, better donor selection
through high-resolution HLA typing including HLA-C in
addition to KIR gene content may improve outcomes and so
move the ﬁeld forward.
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